International Urology and Nephrology

, Volume 46, Issue 6, pp 1115–1121 | Cite as

shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity

  • Peng Jin
  • Jinliang Xie
  • Xiangrong Zhu
  • Cheng Zhou
  • Xiang Ding
  • Luoyan Yang
Urology - Original Paper
First Online:
Received:
Accepted:

Abstract

Purpose

Design short hairpin RNA (shRNA) interference sequence to silence glutathione S-transferase P1 (GSTP1) gene of androgen-independent prostate cancer cell line DU145, and then to explore its effect on sensitivity to chemotherapeutics.

Methods

Target sequence was picked up to form the shRNA. DU145 cell was divided into five groups according to the shRNA added for transfection: shRNA255, shRNA554, shRNA593, negative-shRNA and blank group. Fluorescence microscope was used to pick up the shRNA with the highest transfection ratio. Western blotting and RT-PCR were taken to pick up the shRNA with the best gene silencing result. 3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay and terminal de-oxynucleotidyl transferase-mediated dUTP nick end-labeling assay were used to detect survival ratio and apoptosis ratio of DU145 administered of fluorouracil (5-FU) or paclitaxel (PA) at different concentrations before and after shRNA transfection.

Results

Three different shRNA oligonucleotides (shRNA255; shRNA554; shRNA593) targeting the coding sequence of GSTP1 mRNA and one negative control shRNA were constructed. The transfection ratio of shRNA554 (76.2 ± 0.68 %) was higher than that of shRNA255 (63.3 ± 1.04 %) (P < 0.01) or shRNA593 (72.7 ± 0.33 %) (P < 0.01). After transfection of shRNA554, the mRNA and protein of level were the lowest, P < 0.01. The survival ratio of DU145 administered with 5-FU of different concentrations (30, 60, 120, 240 μg/ml) declined after transfection (P < 0.01). Besides, the apoptosis ratio increased after transfection (P < 0.01). Similarly the survival ratio of DU145 administered with PA of different concentrations (0.2, 2, 10, 20 μg/ml) declined (P < 0.01) and the apoptosis ratio increased (P < 0.01) after transfection.

Conclusions

The gene GSTP1 silence via shRNA transfection to androgen-independent prostate cancer cell line DU145 enhances the sensitivity to chemotherapeutics.

Keywords

Prostate cancer cell line DU145 shRNA GSTP1 Chemotherapeutic sensitivity 
This is a preview of subscription content, log in to check access.

Notes

Conflicts of interest

The authors report no conflicts of interest in this work.

References

  1. 1.
    Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3):481–488PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA: Cancer J Clin 58(2):71–96Google Scholar
  4. 4.
    Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45PubMedCrossRefGoogle Scholar
  5. 5.
    Heidenreich A, von Knobloch R, Hofmann R (2001) Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 39(2):121–130PubMedCrossRefGoogle Scholar
  6. 6.
    Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T (2008) Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis 29(6):1134–1138PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ (2011) Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16(1):74–82PubMedCrossRefGoogle Scholar
  8. 8.
    Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K (2012) Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology 59(113):130–133PubMedCrossRefGoogle Scholar
  9. 9.
    Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE (2003) Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate 56(2):98–105PubMedCrossRefGoogle Scholar
  10. 10.
    Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806–811PubMedCrossRefGoogle Scholar
  11. 11.
    Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14(9):893–900PubMedCrossRefGoogle Scholar
  12. 12.
    Yang Y, Zhou Z, He S, Fan T, Jin Y, Zhu X, Chen C, Zhang ZR, Huang Y (2012) Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-fluorouracil conjugates. Biomaterials 33(7):2260–2271PubMedCrossRefGoogle Scholar
  13. 13.
    Iida K, Zheng R, Shen R, Nanus DM (2012) Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer. Int J Oncol 41(4):1192–1198PubMedCentralPubMedGoogle Scholar
  14. 14.
    Bostwick DG, Meiers I, Shanks JH (2007) Glutathione S-transferase: differential expression of alpha, mu, and pi isoenzymes in benign prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Hum Pathol 38(9):1394–1401PubMedCrossRefGoogle Scholar
  15. 15.
    Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E (2005) Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. The Prostate 63(3):240–251PubMedCrossRefGoogle Scholar
  16. 16.
    O’Brien ML, Vulevic B, Freer S, Boyd J, Shen H, Tew KD (1999) Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 291(3):1348–1355PubMedGoogle Scholar
  17. 17.
    Eilers T, Machtens S, Tezval H, Blaue C, Lichtinghagen R, Hagemann J, Jonas U, Serth J (2007) Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate. Prostate 67(7):757–763PubMedCrossRefGoogle Scholar
  18. 18.
    Lu M, Xia L, Luo D, Waxman S, Jing Y (2004) Dual effects of glutathione-S-transferase-P1 on As203 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 23(22):3945–3952PubMedCrossRefGoogle Scholar
  19. 19.
    Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME (2008) Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 102(3):389–397PubMedCrossRefGoogle Scholar
  20. 20.
    Naiki T, Asamoto M, Toyoda-Hokaiwado N, Naiki-Ito A, Tozawa K, Kohri K, Takahashi S, Shirai T (2012) Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice. Prostate 72(5):533–541PubMedCrossRefGoogle Scholar
  21. 21.
    Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173(1):10–20PubMedCrossRefGoogle Scholar
  22. 22.
    Saleh EM, El-Awady RA, Anis N (2013) Predictive markers for the response to 5-fluorouracil therapy in cancer cells: constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy. Oncol Lett 5(1):321–327PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Peng Jin
    • 1
  • Jinliang Xie
    • 1
  • Xiangrong Zhu
    • 1
  • Cheng Zhou
    • 1
  • Xiang Ding
    • 1
  • Luoyan Yang
    • 2
  1. 1.Centre of Organ Transplantation, Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Department of Urology, Second Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations